Molecular Cancer Therapeutics Chemical and Biological Aspects of Inflammation and Cancer Bridging the Lab and the Clinic in Cancer Medicine
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wang, Z.-G.
Right arrow Articles by Seth, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wang, Z.-G.
Right arrow Articles by Seth, P.
Mol Cancer Ther. 2006;5:367-373
© 2006 American Association for Cancer Research

An oncolytic adenovirus expressing soluble transforming growth factor-ß type II receptor for targeting breast cancer: in vitro evaluation

Zhen-Guo Wang1, Wenli Zhao2, Murali Ramachandra3 and Prem Seth1

1 Laboratory of Gene Therapy, Evanston Northwestern Healthcare Research Institute and Department of Medicine, Evanston Hospital, Northwestern University, Evanston, Illinois; 2 Laboratory of Pathology, Hokkaido University, Sapporo, Hokkaido, Japan; and 3 Canji, Inc., San Diego, California

Requests for reprints: Prem Seth, Laboratory of Gene Therapy, Evanston Northwestern Healthcare Research Institute, Evanston Hospital, Room B624, 2650 Ridge Avenue, Evanston, IL 60201. Phone: 847-570-2317; Fax: 847-733-5256. E-mail: pseth{at}northwestern.edu


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
In recent years, adenoviruses that selectively replicate in tumor cells have been developed. However, there is a tremendous need to improve their anticancer efficacy. We wish to investigate whether a strategy that combines the oncolytic effects of an adenoviral vector with simultaneous expression of soluble form of transforming growth factor-ß type II receptor (sTGFßRII) offers a therapeutic advantage. We chose to target TGF-ßs because they play a pivotal role in late-stage tumorigenesis by enhancing tumor invasion and metastasis. A sTGFßRII cDNA was cloned in conditionally replicating adenoviral vector rAd-sTRII and in a replication-deficient adenovirus Ad-sTRII. Infection of MDA-MB-231 breast cancer cells with rAd-sTRII or Ad-sTRII followed by Western blot analysis indicated the expression of diffused glycosylated forms of sTGFßRII that were also secreted into the extracellular medium. The secreted proteins were shown to bind with TGF-ß and antagonize TGF-ß–induced p38 mitogen-activated protein kinase activity. However, marked differences in the replication potential of rAd-sTRII and Ad-sTRII were observed in breast tumor cells. Infection of MDA-MB-231 cells with rAd-sTRII resulted in cytotoxicity and significant increase in the adenoviral titers that were comparable with a wild-type adenovirus dl309. However, Ad-sTRII was much less toxic to the tumor cells, and the viral titers of Ad-sTRII remained relatively unchanged. These results suggest that the infection of breast tumor cells with conditionally replicating adenoviral vector rAd-sTRII produced sTGFßRII that can abrogate TGF-ß signaling while maintaining the replication potential of the virus, indicating that rAd-sTRII could be a potential anticancer agent. [Mol Cancer Ther 2006;5(2):367–73]


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
In the last several years, there has been a significant interest in using adenoviral vectors for high-level gene expression in the mammalian cells (1–4). Majority of the studies have employed replication-deficient (E1 deleted) adenoviruses expressing the genes of interest (1–4). Recently, adenoviruses that selectively replicate in the tumor cells with certain genetic backgrounds (e.g., tumor cells expressing mutant p53 protein) have been developed (5–7). The selective replication of oncolytic adenovirus in tumor cells amplifies the viral titer, resulting in cell lysis. The released viral particles in turn can infect the neighboring tumor cells, resulting in tumor cytolysis and regression (5–7). Although replicating adenoviruses have an advantage over the replication-deficient adenoviruses (which do not lyse the infected cells and can not spread from cell to cell in a tumor mass), in vivo efficacy of even oncolytic viruses is generally not sufficient for cancer therapy. Therefore, there is a tremendous need to enhance the effectiveness of the oncolytic viruses for cancer therapy.

The long-term goal of this project is to investigate if a conditionally replicating adenovirus (dl01/07) armed with the soluble form of transforming growth factor-ß type II receptor (sTGFßRII) will have an advantage as an antitumor agent for treating breast cancer. We chose to use the dl01/07 mutant because the dl01/07 virus has two deletions in E1A region, one deletion is 4 to 25 amino acids (dl01), and the second deletion is 111 to 123 amino acids (dl07). The resultant E1A proteins can not bind with p300/CBP or pRb proteins (8). Therefore, in primary cells, dl01/07 is ineffective for S-phase induction, and the adenovirus can not replicate. However, cancer cells are able to progress to S phase, thus permitting virus replication in these cells.

We chose to target TGF-ß because TGF-ß plays an important role in late-stage tumorigenesis by stimulating tumor invasion, promoting neoangiogenesis, inducing bone metastasis, and helping cancer cells to escape immunosurveillance (9–19). TGF-ßs have three mammalian isoforms (TGF-ß1, TGF-ß2, and TGF-ß3), each with distinct functions in vivo. After TGF-ß binding to TGFßRII, TGF-ß type I receptor is recruited to the complex. This allows for the constitutively active TGFßRII kinase to transphosphorylate and activate the TGF-ß type I receptor kinase. In breast cancer cells, this initiates the downstream response by various pathways that include SMADs, extracellular signal-regulated kinase-1, extracellular signal-regulated kinase-2, mitogen-activated protein kinases (MAPK), phosphatidylinositol 3-kinase pathways and induces transcriptional modulation of target genes (20, 21). Given the integral role of TGF-ß in the tumor progression, inhibiting TGF-ß signaling emerges as a potential strategy in controlling tumor malignancy for cancer therapy (9, 14, 22, 23).

An oncolytic adenovirus armed with sTGFßRII (rAd-sTRII) was constructed by inserting the soluble 159-amino-acid residue domain of the TGFßRII into the dl01/07 adenoviral genome. As a control for viral replication, we also generated a replication-deficient adenovirus containing sTGFßRII (Ad-sTRII) and a replication-competent dl01/07 expressing herpes simplex virus thymidine kinase (rAd-TK). We investigated if the adenoviral vector–mediated expression of sTGFßRII in the extracellular environment can bind with TGF-ß, resulting in the inhibition of TGF-ß signaling in the target cells.

There was an initial concern that the adenoviral-mediated expression of sTGFßRII protein can potentially interfere with the viral replication. Therefore, one of our goals was to investigate the effect of sTGFßRII expression on the adenoviral replication in breast cancer cells. We examined the cytotoxicity and the replication potential of rAd-sTRII and Ad-sTRII in breast tumor cells. Our results suggest that whereas the infection of breast tumor cells with rAd-sTRII and Ad-sTRII produced the functional sTGFßRII protein, only the rAd-sTRII replicated in the tumor cells. Thus, it is possible to simultaneously achieve the adenoviral replication and the expression of the secreted form of functional sTGFßRII protein, indicating the potential use of rAd-sTRII for cancer therapy.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Cell Culture
HEK-293 (ATCC CRL-1573), SK-BR-3, MDA-MB-468, MDA-MB-453, T47D, MCF-7, and MDA-MB-231 (kindly provided by Ruth Lupu, Evanston Northwestern Healthcare Research Institute) were cultured in DMEM (Mediatech, Inc., Herndon, VA) containing 10% fetal bovine serum (FBS; Mediatech) and 1% penicillin/streptomycin (Invitrogen, Carlsbad, CA).

Adenoviruses
For construction of replication-deficient adenovirus Ad-sTRII, ~0.5-kb NotI-HindIII DNA fragment containing codon 1-159 of the TGFßRII gene from pBS-SK(–)/sTRII (24) was cloned in the NotI and HindIII region of pShuttle-CMV. The resulting shuttle vector pShuttle-CMV/sTRII was then recombined in Escherichia coli BJ5183 by homologous recombination with the E1- and E3-deleted pAdEasy-1 adenoviral backbone vector (Stratagene, La Jolla, CA) to generate a packagable adenoviral genome pAd-sTRII (25). Ad-sTRII vector was produced by transfecting PacI-digested pAd-sTRII into HEK-293 cells by LipofectAMINE 2000 (Invitrogen). For construction of replication-competent adenovirus rAd-sTRII, ~550-bp XbaI fragment from pShuttle-CMV/sTRII containing codon 1-159 of the TGFßRII gene was cloned in XbaI-cut plasmid p309-CMV-poly(A) to produce a shuttle vector p309/sTRII. The 11-kb PacI-AscI fragment from p309/sTRII was recombined with BstBI- and SpeI-cut adenoviral backbone plasmid pTG07-4609 in E. coli BJ5183 to produce adenoviral genome plasmid pTG07-4609/sTRII. Adenovirus rAd-sTRII was generated by transfecting PacI-cut pTG07-4609/sTRII into HEK-293 cells. rAd-TK was constructed by similar procedures except that the herpes simplex virus thymidine kinase (HSV-TK) gene was inserted instead of the sTGFßRII gene. E1-deleted replication-deficient adenovirus devoid of any foreign cDNA (AdNull) was described previously (26). dl309 is a phenotypically wild-type adenovirus (27). Adenoviruses were amplified in HEK-293 cells and purified by cesium chloride gradient ultracentrifugation, and the titers were calculated using published methods (28, 29).

Expression of sTGFßRII from MDA-MB-231 Cells
MDA-MB-231 cells (1 x 106 per well in six-well plate) were plated in DMEM containing 10% FBS and incubated at 37°C overnight. The next morning, cells were infected with 100 plaque-forming units/cell (unless otherwise mentioned) of adenovirus for 3 hours. Cells were washed and incubated with DMEM without FBS for 24 hours. Media and cells were separately dissolved in SDS sample buffer and subjected to Western blot analysis as previously described (28, 30). Blots were probed with antibody reactive against TGFßRII (H-567; Santa Cruz Biotechnology, Santa Cruz, CA) or actin protein (I-19; Santa Cruz Biotechnology).

Treatment of sTGFßRII with PNGase F
Sixty microliters of culture media from Ad-sTRII or rAd-sTRII infected MDA-MB-231 cells were denatured at 100°C for 10 minutes and treated with PNGase F (New England Biolabs, Beverly, MA) for 2 hours at 37°C according to manufacturer's instructions. The proteins were subjected to SDS-PAGE and analyzed by Western blot using rabbit anti-TGFßRII polyclonal antibody.

TGF-ß1 binding by sTGFßRII
MDA-MB-231 cells (1 x 106 per well in six-well plate) were uninfected or infected with different adenoviruses [100 multiplicities of infection (MOI)] for 3 hours in growth media. Cells were washed and incubated in 1.7 mL serum-free DMEM medium for 20 hours. The culture media were collected, and 200 µL of culture media were mixed with TGF-ß1 (40 ng; Sigma, St. Louis, MO) for 1 hour at 4°C and 50 µL of wheat germ agglutinin-Sepharose agarose beads (Vector Laboratories, Burlingame, CA) were added and incubated for 1 hour at 4°C. The beads were washed six times with buffer [50 mmol/L NaCl, 10 mmol/L Tris-HCl, 5 mmol/L EDTA, 1% Triton X-100 (pH 7.4)] and subjected to SDS-PAGE (15%). The proteins were transferred onto Immun-Blot polyvinylidene difluoride membranes (Bio-Rad, Hercules, CA) and probed with rabbit anti-TGF-ß1 polyclonal antibody (Promega, Madison, WI).

p38 MAPK Activation in MDA-MB-231 Cells by TGF-ß1
MDA-MB-231 cells grown in normal growth medium were serum starved overnight in DMEM without FBS, washed, and incubated fresh DMEM without FBS. TGF-ß1 (5 ng/mL) was added to the cells and incubated for 0, 10, 20, 30, 60, 120, 180, and 240 minutes at 37°C. The total cells were subjected to Western blot using antibodies against phospho-p38 (sc-7975-R, Santa Cruz Biotechnology) or p38 (C-20, Santa Cruz Biotechnology).

Effects on p38 MAPK Activation by Cultured Media from Virus-Infected Cells
MDA-MB-231 cells were incubated with 100 MOI of different adenoviruses for 3 hours in normal growth medium. Cells were washed and incubated in serum-free DMEM for 20 hours. The culture media were collected and centrifuged at 180,000 x g to remove contaminating adenovirus in the media. The 0.1 mL of this culture media was mixed with 0.7 mL DMEM without FBS and transferred to serum-starved MDA-MB-231 cells and incubated at 37°C for 1 hour. Cells were washed and dissolved in SDS sample buffer for Western blot analysis of p38 MAPK activation.

Cytotoxicity Assay
Cells were plated in triplicate in 96-well dishes (500 per well) and incubated for 24 hours at 37°C. Cells were exposed to varying concentrations of Ad-sTRII and rAd-sTRII and incubated for additional 7 days at 37°C. A colorimetric assay was done as described previously (28). Briefly, cells were fixed in 10% trichloroacetic acid for 1 hour, washed five times with water, and allowed to air dry. Cells were then stained for 10 minutes with 0.4% sulforhodamine B (Sigma), dissolved in 1% acetic acid, and rinsed five times with 1% acetic acid. Absorbance (A564 nm) was obtained using Spectramax 250 (Molecular Devices, Sunnyvale, CA), which was used as a measure of cell number. The IC50 (viral dose that caused 50% cytotoxicity) was calculated assuming the survival rate of uninfected cells to be 100%. The ratio of IC50 was calculated by dividing the IC50 of cells infected with Ad-sTRII by the IC50 of cells infected with rAd-sTRII for each cell line.

Viral Production Assay
To assay for viral replication, MDA-MB-231 cells were plated in six-well plates at about 70% confluence and then infected with Ad-sTRII, rAd-sTRII, rAd-TK, or dl309 for 3 hours at an MOI of 50, washed once with DMEM, and incubated in 1 mL DMEM for additional 1 hour at 37°C. At the end of the incubation, cells were washed and divided into two groups. In one group, cells were collected in 0.5 mL growth media and frozen at –70°C. In the second group, cells were maintained in growth media for additional 48 hours. Media and cells in both groups were collected, and cells were subjected to three cycles of freezing and thawing to release the viruses. The total viruses from media and cells were serially diluted and added to monolayers of 293 cells, respectively. After 3 hours of incubation at 37°C, the infected 293 cells were overlaid with 3 mL 1.25% SeaPlaque agarose (Cambrex, East Rutherford, NJ) in growth media. Plaques were counted following 7 to 10 days of incubation using published methods (29).


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
Construction of Ad-sTRII and rAd-sTRII
The recombinant adenoviruses Ad-sTRII and rAd-sTRII were constructed as described in Materials and Methods. To generate Ad-sTRII and rAd-sTRII, the cDNA for the complete extracellular domain of human TGFßRII (amino acid residues 1–159) under the control of cytomegalovirus promoter (CMV) was placed in their individual genomes. The schematic diagram of the structure of adenoviruses is shown in Fig. 1 . It should be noted that the replication-deficient Ad-sTRII vector has an E1 deletion, whereas rAd-sTRII is a conditionally replicating adenovirus due to two short deletions in the E1A gene (dl01/07; Fig. 1; ref. 8).


Figure 1
View larger version (30K):
[in this window]
[in a new window]
  		Figure 1. Schematic diagram of adenoviral constructs. The gene for the sTGFßRII (amino acids 1–159) under the control of CMV promoter was inserted in the E3 region in rAd-sTRII adenoviral vector and in the E1 region in Ad-sTRII adenoviral vector. rAd-sTRII has two small deletions ({diamond} {diamond}) 4 to 25 and 111 to 123 amino acids in E1A protein (dl01/07) and RID-{alpha}, ß, and 14.7K protein deletions in E3 region. Ad-sTRII is an E1, E3-deleted adenovirus. The maps were not drawn to scale.

 
Adenovirus-Mediated Expression of sTGFßRII
We investigated whether the infection of human breast cancer cells with Ad-sTRII and rAd-sTRII can produce sTGFßRII protein. MDA-MB-231 breast cancer cells were exposed to AdNull, Ad-sTRII, or rAd-sTRII for 24 hours and subjected to Western blot analysis. As shown in Fig. 2A , there were no detectable protein bands reactive with antibody against TGFßRII in cells infected with AdNull. In contrast, strong protein bands appeared in both Ad-sTRII– and rAd-sTRII–infected cells. In cell lysates, there were protein bands with molecular weight ranging from 20 to 25 kDa, whereas in cell media, protein bands shifted to the higher position with molecular weight ranging from 20 to 40 kDa. Figure 2B and C shows the dose-dependent increase of sTGFßRII expression in both media and cell lysates. Infection of other breast tumor cells with these viruses also resulted in the overexpression of sTGFßRII (data not shown).


Figure 2
View larger version (37K):
[in this window]
[in a new window]
  		Figure 2. Expression of sTGFßRII from MDA-MB-231 cells. A, MDA-MB-231 cells were incubated with replication-deficient AdNull or Ad-sTRII or oncolytic rAd-sTRII (100 MOI) for 3 h and washed, and DMEM without serum was added to the cells and incubated for 24 h. B and C, MDA-MB-231 cells were incubated with different dosages of Ad-sTRII or rAd-sTRII (0, 1, 5, 25, 100, and 200 MOI) for 3 h and washed and DMEM without serum was added to the cells and incubated for 24 h. Culture media and cells were collected separately for Western blot analysis using antibodies against TGFßRII. The protein loading in each lane from cell lysates was determined by probing ß-actin. MW, molecular weight.

 
The predicted molecular mass of truncated TGFßRII (amino acid residues 1–159) is around 18 kDa. After cleavage of the hydrophobic leader sequence, the length of this truncated receptor is 136-amino-acid residues, and the predicted molecular mass is ~15.5 kDa. However, as described above, in our experiments, the cells did not produce a distinct band, but instead, a smear of high molecular weight was observed. It was previously reported that the secreted soluble receptor contains complex N-linked oligosaccharides as well as additional sialic acid residues (31). We treated the secreted sTGFßRII receptor from both Ad-sTRII– and rAd-sTRII–infected cells with N-glycosidase F (PNGase F), an amidase that cleaves between the innermost GlcNAc and asparagine residues of high-mannose, hybrid, and complex oligosaccharides from N-linked glycoproteins (32). The protein smear was resolved into two major distinct bands (~25 and ~20 kDa), indicating that the sTGFßRII produced by MDA-MB-231 is a heterogeneously glycosylated protein (Fig. 3 ).


Figure 3
View larger version (55K):
[in this window]
[in a new window]
  		Figure 3. Deglycosylation of sTGFßRII. Culture media from Ad-sTRII– or rAd-sTRII–infected MDA-MB-231 cells were treated with PNGase F (+) or left untreated (–). The proteins were subjected to SDS-PAGE and analyzed by Western blot for sTGFßRII using antibody against TGFßRII.

 
TGF-ß Binding and Inhibition of p38 MAPK Phosphorylation by sTGFßRII
To test whether sTGFßRII could bind to TGF-ß, cells were infected with adenoviruses (100 plaque-forming units/cell for 24 hours). sTGFßRII is known to bind with TGF-ß1 with much higher affinity compared with TGF-ß2 (33). The culture media from uninfected or infected cells were incubated with pure recombinant TGF-ß1 and mixed with wheat germ agglutinin-Sepharose beads, which bind to glycosylated proteins, including soluble TGF-ß receptor. Beads were washed and subjected to Western blot analysis and probed with anti–TGF-ß1 antibody. TGF-ß1 was clearly detectable in the precipitate from the medium of soluble TGF-ß receptor expressing cells but not from the uninfected or AdNull-infected cells (Fig. 4A ). These results indicate that the secreted soluble TGF-ß receptor can bind with TGF-ß.


Figure 4
View larger version (49K):
[in this window]
[in a new window]
  		Figure 4. Binding of TGF-ß and inhibition of p38 MAPK phosphorylation by sTGFßRII. A, culture media from uninfected or infected MDA-MB-231 cells were incubated with recombinant TGF-ß1 protein (40 ng) and mixed with wheat germ agglutinin-Sepharose beads. After extensive washing, the beads were subjected to SDS-PAGE (15%) and analyzed by Western blot using an antibody against TGF-ß1. A recombinant TGF-ß1 protein was included as positive control. B, serum-starved MDA-MB-231 cells were stimulated with TGF-ß1 for various times (0, 10, 20, and 30 min and 1, 2, 3, and 4 h). C, serum-starved MDA-MB-231 cells were treated for 1 h with culture media obtained from AdNull-, Ad-sTRII–, or rAd-sTRII–infected MDA-MB-231 cells. Culture media from MDA-MB-231 cells without Ad infection served as control. Amount of phospho-p38 and total p38 was analyzed by Western blot using antibodies specific for phosphorylated and total p38 MAPK.

 
Next, we wanted to investigate if the binding of soluble TGF-ß receptor with TGF-ß will abolish TGF-ß signaling in breast cancer cells. Although several biochemical pathways are involved in TGF-ß signaling, we chose to specifically examine p38 MAPK because the latter is known to be involved in TGF-ß signaling in MDA-MB-231 cells (34). We examined the activation of p38 MAPK by TGF-ß in Western blot assays. Antibodies specific for nonphosphorylated and phosphorylated p38 MAPK were used. As shown in Fig. 4B, the phosphorylation of p38 MAPK was increased in MDA-MB-231 cells after TGF-ß1 addition to the media with maximal activation at 30 to 60 minutes. To test whether soluble TGF-ß receptor produced by virus-infected cells can functionally inhibit TGF-ß activities, we assessed its effect on p38 MAPK phosphorylation in MDA-MB-231 cells. MDA-MB-231 cells cultured in serum-free medium secrete multiple growth factors and cytokines, including TGF-ß (35). Cells were infected with 100 MOI of either Ad-sTRII or rAd-sTRII for 24 hours. Culture media from the virally infected cells were collected and centrifuged at 180,000 x g. Under these conditions, adenoviruses are known to sediment at the bottom of the centrifuge tube (36). The overnight culture media from uninfected or virus-infected cells were used to treat new set of MDA-MB-231 cells for 1 hour. The cells treated with the culture media from both Ad-sTRII– and rAd-sTRII–infected cells exhibited decreased phosphorylation of p38 MAPK compared with cells treated with media from AdNull-infected or uninfected cells (Fig. 4C). These results indicate that the binding of TGF-ß by sTGFßRII in the culture media prevented the maximal activation of p38 MAPK.

Adenoviral-Mediated Cytotoxicity and Viral Replication in Breast Tumor Cells
For cancer therapy purposes, it is important that rAd-sTRII–mediated production of soluble TGF-ß RII does not compromise with the viral replication in the target cells. We therefore investigated the effect of adenoviral infections on the viral replication in two different assays: an indirect cytotoxicity assay and a direct method to evaluate the viral titers. To investigate the viral-mediated cytotoxicity, several breast tumor cell lines were exposed to varying doses of adenoviruses shown in Fig. 5A and B . The cytotoxicity assays were done as described in Material and Methods. In MDA-MB-231 cells, rAd-sTRII caused a dose-dependent increase in the cytotoxicity and markedly inhibited cell growth even at viral dosage levels <100 MOI. Under similar conditions, much higher doses of Ad-sTRII were required to induce comparable cytotoxicity. Similarly, rAd-sTRII was relatively more cytotoxic than Ad-sTRII in MCF-7 breast cancer cells. To investigate the contribution of sTGFßRII in cell killing, we compared the effect of rAd-sTRII with a control replicating adenovirus, rAd-TK. Both viruses exerted cytotoxic effect on the cells in a similar dose-dependent manner. In addition, we also compared the basal level toxicity of first-generation E1-deleted adenovirus expressing sTGFßRII with a control E1-deleted adenovirus devoid of any transgene. In this comparison, also nearly equal cytotoxicity to the tumor cells was observed. Thus, it seems that in our assay, sTGFßRII overexpression did not enhance the cytotoxicity of oncolytic or replication-deficient adenoviruses. Figure 5C shows the ratio of IC50 caused by Ad-sTRII and rAd-sTRII in different breast tumor cell lines. These marked differences in cytotoxicity (5- to 500-fold) inflicted by rAd-sTRII were presumably the result of virus replication in these cancer cells.


Figure 5
View larger version (18K):
[in this window]
[in a new window]
  		Figure 5. Cytotoxicity of recombinant adenoviruses to breast cancer cells. Effect of different adenoviruses on cell growth was assayed by plating breast cancer cells (500 per well) in triplicate in 96-well plates. Cells were infected with AdNull, Ad-sTRII, rAd-TK, or rAd-sTRII for 7 d and stained as described in Materials and Methods. A, MDA-MB-231 cells. B, MCF-7 cells. C, IC50 ratio between Ad-sTRII and rAd-sTRII was calculated for different breast cancer cell lines. Points, mean of three separate experiments, each conducted in triplicate; bars, SE.

 
To assess the replication ability of rAd-sTRII in a direct assay, we compared the vial production of rAd-sTRII with that of Ad-sTRII and two control adenoviruses rAd-TK and dl309 in MDA-MB-231 cells. The total viral particles in the culture medium and cell fraction were determined by performing plaque assay on 293 cells. After 48 hours of virus infection, the viral yield increased significantly (about 4 log differences compared with that of a 3-hour incubation) for rAd-sTRII, rAd-TK, and dl309 adenoviruses (Fig. 6 ). The titer of rAd-sTRII is only slightly lower than that of rAd-TK and was comparable with that of dl309. In contrast, the titer for replication-deficient Ad-sTRII did not increase but rather slightly decreased after a 48-hour incubation, indicating the inability of Ad-sTRII to replicate in MDA-MB-231 cells. These results suggest that the expression of sTGFßRII does not discernibly inhibit the replication of rAd-sTRII in MDA-MB-231 cells.


Figure 6
View larger version (32K):
[in this window]
[in a new window]
  		Figure 6. Replication of adenoviruses in MDA-MB-231 cells. MDA-MB-231 cells were infected with different viruses for 3 and 48 h. Both media and cells were recovered and processed for the release of viruses. Viral titer was determined on HEK-293 cells by plaque assay. Columns, mean of three separate experiments, each done in duplicates; bars, SE. Inset, the fold increase in viral titers from 3 to 48 h incubation.

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
In recent years, replication-competent oncolytic adenoviral vectors as potential antitumor agents have been developed. To augment the anticancer effects of replicating adenoviruses, oncolytic adenoviruses can be armed with other genes, such as suicide genes, in a manner similar to the extensive development of the recombinant replication-deficient adenoviruses (1–4, 37). In this report, we have successfully placed the sTGFßRII gene in the genome of a replication-competent adenovirus and a control replication-deficient adenovirus and have conducted in vitro evaluation in breast tumor cells.

The sTGFßRII was overexpressed in breast cancer cells after infection with rAd-sTRII adenoviral vector. Vector-mediated expression of sTGFßRII was dependent on the viral dose. Western blot analysis of the infected cells indicated multiple size protein bands. However, the multiple protein bands were not due to the degradation product(s) of the sTGFßRII but due to the glycosylation of the sTGFßRII, as the treatment of the secreted proteins with N-glycosidase F converted the various heterogeneous bands into two distinct protein bands. More importantly, the secreted sTGFßRII protein was shown to bind with TGF-ß1 and inhibited TGF-ß–stimulated p38 MAPK in the target cells, suggesting that the sTGFßRII was fully functional. Similar levels of sTGFßRII functional proteins were produced by replication-deficient and replication-competent adenoviruses, suggesting that the viral replication had no adverse effect on the expression of sTGFßRII protein.

Overexpression of TGF-ß ligands has been reported in many tumor types and elevated levels of TGF-ß in tumor tissues correlate with markers of a more metastatic phenotype and/or poor patient outcome (38, 39). Based on our in vitro observations that rAd-sTRII–mediated expression and secretion of sTGFßRII into the extracellular environment can inhibit TGF-ß signaling, we can perceive that the administration of rAd-sTRII in vivo will produce sTGFßRII that will be systemically released into the blood. This will inactivate the "overactive" TGF-ß signaling associated with breast cancers and will result in the inhibition of tumor invasion and metastasis. However, in the absence of any experimental data, this remains an exciting hypothesis that needs to be tested in future.

In this study, we have shown that the rAd-sTRII is fully replication competent compared with a phenotypically wild type adenovirus dl309. It is an important observation given a tight interaction of the cellular machinery with the adenoviral replication heterologous protein can potentially interfere with the adenoviral replication, defeating the main advantage of replicating adenoviral vectors. Because the commonly used conditionally replicating viruses often exploit the differences in the cell cycle status, programmed cell death, and the cellular DNA synthesis between normal and tumor cells, the heterologous protein can potentially interact with these cellular pathways/machinery and interfere with adenoviral replication even in the tumor cells. Examples of such proteins are the regulators of cell cycle (p16INK4A and p21WAF1/Cip1), apoptosis (wild-type p53 and Bax), and DNA and protein synthesis (suicide gene plus the pro-drugs). Given the multiple pathways involved in the TGF-ß–mediated signaling, there was a possibility that interfering with TGF-ß pathways would the adenoviral replication. In this regard, it is a significant finding that overexpression of vector-mediated sTGFßRII does not compromise with the adenoviral replication in the limited number of breast tumor cells that we have tested thus far. However, it was surprising that sTGFßRII overexpression did not enhance the cytotoxic effect of the oncolytic virus. Although the exact reasons for this were not explored, in the future, we would further investigate this important observation.

Another point worth noting is the choice of the replicating adenoviral mutant to overexpress the transgene of interest. We chose to use dl01/07 adenovirus backbone, because dl01/07 expresses the mutant E1A gene product that is defective for binding both p300/CBP and pRb. pRb and p300 regulate the activity of E2F, which activates genes involved in transition from G1 phase to the S phase of the cell cycle. All tumor cells exhibit uncontrolled cell growth due to deregulated G1-S phase transition of the cell cycle. In cycling tumor cells, E2F is constitutively active because of disruption in the pRb/p16INK4a/cyclin D pathway, including E2F-1 gene amplification. Therefore, dl01/07 can replicate in the tumor cells regardless of their genetic background (40), making it an attractive vector for treating a variety of cancers.

In summary, the rAd-sTRII replication in the infected cells and simultaneous production and release of sTGFßRII in the extracellular medium resulting in the inhibition of TGF-ß signaling in the target cells offer us potentially a powerful tool to simultaneously treat the primary tumor and metastasis in breast cancer. In the future, we wish to take up this important endeavor to investigate the feasibility of using rAd-sTRII vector as an antitumor agent using the animal models and eventually in the clinical setting. Although in these studies, we have focused on the breast cancer cells as the target, it is likely that rAd-sTRII will find applications in targeting many cancers, especially those malignancies in which TGF-ß overexpression seems to enhance tumorigenesis.


   Acknowledgments
 
We thank Dr. Janardan D. Khandekar for his support of this research.


   Footnotes
 
Grant support: Department of Defense Breast Cancer Research Program Award DAMAD17-03-0703, NIH grant R21CA112588-01A1, Evanston Northwestern Healthcare Auxiliary Breast Cancer Research, and Evanston Northwestern Healthcare Research Career Development Award (P. Seth).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Note: The current address for W. Zhao is the Department of Microbiology, Columbia University, New York, New York.

Received 4/25/05; revised 10/31/05; accepted 11/22/05.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Seth P, editor. Adenoviruses: basic biology to gene therapy. Austin (TX): R G Landes Company; 1999. p. 1–314.
  2. Seth P. Adenoviral vectors. Adv Exp Med Biol 2000;465:13–22.[Medline]
  3. Hitt MM, Graham FL. Adenovirus vectors for human gene therapy. Adv Virus Res 2000;55:479–505.[Medline]
  4. Imperiale MJ, Kochanek S. Adenovirus vectors: biology, design, and production. Curr Top Microbiol Immunol 2004;273:335–57.[Medline]
  5. Bischoff JR, Kirn DH, Williams A, et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996;274:373–6.[Abstract/Free Full Text]
  6. Biederer C, Ries S, Brandts CH, McCormick F. Replication-selective viruses for cancer therapy. J Mol Med 2002;80:163–75.[CrossRef][Medline]
  7. Post DE, Khuri FR, Simons JW, Van Meir EG. Replicative oncolytic adenoviruses in multimodal cancer regimens. Hum Gene Ther 2003;14:933–46.[CrossRef][Medline]
  8. Howe JA, Mymryk JS, Egan C, Branton PE, Bayley ST. Retinoblastoma growth suppressor and a 300-kDa protein appear to regulate cellular DNA synthesis. Proc Natl Acad Sci U S A 1990;87:5883–7.[Abstract/Free Full Text]
  9. Muraoka-Cook RS, Dumont N, Arteaga CL. Dual role of transforming growth factor beta in mammary tumorigenesis and metastatic progression. Clin Cancer Res 2005;11:937–43s.
  10. Roberts AB, Wakefield LM. The two faces of transforming growth factor beta in carcinogenesis. Proc Natl Acad Sci U S A 2003;100:8621–3.[Free Full Text]
  11. Akhurst RJ, Derynck R. TGF-beta signaling in cancer: a double-edged sword. Trends Cell Biol 2001;11:S44–51.[Medline]
  12. Inge TH, Hoover SK, Susskind BM, Barrett SK, Bear HD. Inhibition of tumor-specific cytotoxic T-lymphocyte responses by transforming growth factor beta 1. Cancer Res 1992;52:1386–92.[Abstract/Free Full Text]
  13. Wojtowicz-Praga S. Reversal of tumor-induced immunosuppression by TGF-beta inhibitors. Invest New Drugs 2003;21:21–32.[CrossRef][Medline]
  14. Iyer I, Wang Z-G, Akhtari M, Zhao W, Seth P. Targeting TGF beta signaling for cancer therapy. Cancer Biol Ther 2005;4:e33–8.
  15. Guise TA, Chirgwin JM. Transforming growth factor-beta in osteolytic breast cancer bone metastases. Clin Orthop Relat Res 2003;S32–8.
  16. Yin JJ, Selander K, Chirgwin JM, et al. TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest 1999;103:197–206.[Medline]
  17. Ishida A, Fujita N, Kitazawa R, Tsuruo T. Transforming growth factor-beta induces expression of receptor activator of NF-kappa B ligand in vascular endothelial cells derived from bone. J Biol Chem 2002;277:26217–24.[Abstract/Free Full Text]
  18. Teicher BA. Malignant cells, directors of the malignant process: role of transforming growth factor-beta. Cancer Metastasis Rev 2001;20:133–43.[CrossRef][Medline]
  19. Muraoka RS, Dumont N, Ritter CA, et al. Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases. J Clin Invest 2002;109:1551–9.[CrossRef][Medline]
  20. Massague J, Wotton D. Transcriptional control by the TGF-beta/Smad signaling system. EMBO J 2000;19:1745–54.[CrossRef][Medline]
  21. Siegel PM, Massague J. Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat Rev Cancer 2003;3:807–21.[CrossRef][Medline]
  22. Yingling JM, Blanchard KL, Sawyer JS. Development of TGF-beta signalling inhibitors for cancer therapy. Nat Rev Drug Discov 2004;3:1011–22.[CrossRef][Medline]
  23. Dumont N, Arteaga CL. Targeting the TGF beta signaling network in human neoplasia. Cancer Cell 2003;3:531–6.[CrossRef][Medline]
  24. Zhao W, Kobayashi M, Ding W, et al. Suppression of in vivo tumorigenicity of rat hepatoma cell line KDH-8 cells by soluble TGF-beta receptor type II. Cancer Immunol Immunother 2002;51:381–8.[CrossRef][Medline]
  25. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A 1998;95:2509–14.[Abstract/Free Full Text]
  26. Li Z, Shanmugam N, Katayose D, et al. Enzyme/prodrug gene therapy approach for breast cancer using a recombinant adenovirus expressing Escherichia coli cytosine deaminase. Cancer Gene Ther 1997;4:113–7.[Medline]
  27. Bett AJ, Krougliak V, Graham FL. DNA sequence of the deletion/insertion in early region 3 of Ad5 dl309. Virus Res 1995;39:75–82.[CrossRef][Medline]
  28. Katayose D, Gudas J, Nguyen H, Srivastava S, Cowan KH, Seth P. Cytotoxic effects of adenovirus-mediated wild-type p53 protein expression in normal and tumor mammary epithelial cells. Clin Cancer Res 1995;1:889–97.[Abstract]
  29. Seth P, Higginbotham J. Advantages and disadvantages of multiple different methods of adenoviral vector construction. In: Habib N, editor. Methods in molecular medicine. Vol. 45. Totowa (NJ): Humana Press, Inc; 2000. p. 189–98.
  30. Craig C, Wersto R, Kim M, et al. A recombinant adenovirus expressing p27Kip1 induces cell cycle arrest and loss of cyclin-Cdk activity in human breast cancer cells. Oncogene 1997;14:2283–9.[CrossRef][Medline]
  31. Lin HY, Moustakas A, Knaus P, Wells RG, Henis YI, Lodish HF. The soluble exoplasmic domain of the type II transforming growth factor (TGF)-beta receptor. A heterogeneously glycosylated protein with high affinity and selectivity for TGF-beta ligands. J Biol Chem 1995;270:2747–54.[Abstract/Free Full Text]
  32. Maley F, Trimble RB, Tarentino AL, Plummer TH, Jr. Characterization of glycoproteins and their associated oligosaccharides through the use of endoglycosidases. Anal Biochem 1989;180:195–204.[CrossRef][Medline]
  33. Tsang ML, Zhou L, Zheng BL, et al. Characterization of recombinant soluble human transforming growth factor-beta receptor type II (rhTGF-beta sRII). Cytokine 1995;7:389–97.[CrossRef][Medline]
  34. Kakonen SM, Selander KS, Chirgwin JM, et al. Transforming growth factor-beta stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways. J Biol Chem 2002;277:24571–8.[Abstract/Free Full Text]
  35. Pederson L, Winding B, Foged NT, Spelsberg TC, Oursler MJ. Identification of breast cancer cell line-derived paracrine factors that stimulate osteoclast activity. Cancer Res 1999;59:5849–55.[Abstract/Free Full Text]
  36. Seth P. Mechanism of adenovirus-mediated endosome lysis: role of the intact adenovirus capsid structure. Biochem Biophys Res Commun 1994;205:1318–24.[CrossRef][Medline]
  37. Roth JA, Grammer SF. Tumor suppressor gene therapy. Methods Mol Biol 2003;223:577–98.[Medline]
  38. Ivanovic V, Todorovic-Rakovic N, Demajo M, et al. Elevated plasma levels of transforming growth factor-beta 1 (TGF-beta 1) in patients with advanced breast cancer: association with disease progression. Eur J Cancer 2003;39:454–61.[CrossRef][Medline]
  39. Gold LI. The role for transforming growth factor-beta (TGF-beta) in human cancer. Crit Rev Oncog 1999;10:303–60.[Medline]
  40. Howe JA, Demers GW, Johnson DE, et al. Evaluation of E1-mutant adenoviruses as conditionally replicating agents for cancer therapy. Mol Ther 2000;2:485–95.[CrossRef][Medline]




This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wang, Z.-G.
Right arrow Articles by Seth, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wang, Z.-G.
Right arrow Articles by Seth, P.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online